english.prescrire.org > Spotlight > 100 most recent > Herpes zoster vaccine gE/AS01B (Shingrix°)

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Herpes zoster vaccine gE/AS01B (Shingrix°)

 Marketing Authorisations   The main complication of herpes zoster is persistent neuropathic pain, which can last for months or even years. Immunocompromised patients are at higher risk of developing this complication. Attenuated varicella-zoster virus vaccine is contraindicated in immunocompromised patients, due to the risk of infection with the attenuated virus. A protein vaccine has now been authorised for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 years or older and in adults at increased risk of herpes zoster from 18 years of age.
Full article available for download by subscribers (4 pages)

©Prescrire 1 November 2024

Source: "Herpes zoster vaccine gE/AS01B (Shingrix°)" Prescrire Int 2024; 33 (264): 260-263. Subscribers only.

Enjoy full access to Prescrire International, and support independent information

 
Share
Share on Facebook Share on Twitter
 
 
See also:

"Herpes zoster vaccine.
Poorly effective in those who
need it most"
Prescrire Int 2012;